Liang Xiuming, Gupta Dhanu, Xie Junhua, Van Wonterghem Elien, Van Hoecke Lien, Hean Justin, Niu Zheyu, Ghaeidamini Marziyeh, Wiklander Oscar P B, Zheng Wenyi, Wiklander Rim Jawad, He Rui, Mamand Doste R, Bost Jeremy, Zhou Guannan, Zhou Houze, Roudi Samantha, Estupiñán H Yesid, Rädler Julia, Zickler Antje M, Görgens André, Hou Vicky W Q, Slovak Radka, Hagey Daniel W, de Jong Olivier G, Uy Aileen Geobee, Zong Yuanyuan, Mäger Imre, Perez Carla Martin, Roberts Thomas C, Carter Dave, Vader Pieter, Esbjörner Elin K, de Fougerolles Antonin, Wood Matthew J A, Vandenbroucke Roosmarijn E, Nordin Joel Z, El Andaloussi Samir
Division for Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska ATMP Center, ANA Futura, Karolinska Institutet, Stockholm, Sweden.
Nat Commun. 2025 Apr 29;16(1):4028. doi: 10.1038/s41467-025-59377-y.
Intracellular delivery of protein and RNA therapeutics represents a major challenge. Here, we develop highly potent engineered extracellular vesicles (EVs) by incorporating bio-inspired attributes required for effective delivery. These comprise an engineered mini-intein protein with self-cleavage activity for active cargo loading and release, and fusogenic VSV-G protein for endosomal escape. Combining these components allows high efficiency recombination and genome editing in vitro following EV-mediated delivery of Cre recombinase and Cas9/sgRNA RNP cargoes, respectively. In vivo, infusion of a single dose Cre loaded EVs into the lateral ventricle in brain of Cre-LoxP R26-LSL-tdTomato reporter mice results in greater than 40% and 30% recombined cells in hippocampus and cortex respectively. In addition, we demonstrate therapeutic potential of this platform by showing inhibition of LPS-induced systemic inflammation via delivery of a super-repressor of NF-ĸB activity. Our data establish these engineered EVs as a platform for effective delivery of multimodal therapeutic cargoes, including for efficient genome editing.
蛋白质和RNA治疗药物的细胞内递送是一项重大挑战。在此,我们通过整合有效递送所需的仿生特性,开发出了高效的工程化细胞外囊泡(EVs)。这些特性包括一种具有自切割活性的工程化小内含肽蛋白,用于活性货物的装载和释放,以及用于内体逃逸的融合性水泡性口炎病毒糖蛋白(VSV-G)。将这些成分结合起来,分别在EV介导的Cre重组酶和Cas9/sgRNA核糖核蛋白(RNP)货物递送后,能够在体外实现高效重组和基因组编辑。在体内,将单剂量负载Cre的EVs注入Cre-LoxP R26-LSL-tdTomato报告基因小鼠大脑的侧脑室后,海马体和皮层中分别有超过40%和30%的细胞发生重组。此外,我们通过递送NF-κB活性的超级抑制剂来抑制脂多糖(LPS)诱导的全身炎症,从而证明了该平台的治疗潜力。我们的数据表明,这些工程化EVs可作为一个有效递送多模式治疗货物的平台,包括用于高效基因组编辑。